EIF2S2

Across TCGA pan-cancer cohorts, EIF2S2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EIF2S2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EIF2S2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF2S2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, GBM, and PDAC are the cancer types where EIF2S2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.916	0.208	.006	21	view →
GBM	DFS	Tertile	All	0.178	0.327	.010	13	view →
PDAC	DFS	Median	III,IV	0.376	0.690	.018	9	view →
CCRCC	DFS	Tertile	All	0.625	0.857	.008	6	view →
UCEC	DFS	Tertile	All	0.838	0.953	.027	2	view →
HNSC	DFS	Tertile	III,IV	0.691	0.881	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EIF2S2–LUAD (DFS)

Open the LUAD breakdown →